Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial - Concepedia

Concepedia

Publication | Closed Access

Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

936

Citations

6

References

2006

Year

Ian M. Thompson, Donna P. Ankerst, Chi Chen, Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, Ziding Feng, Howard L. Parnes, Charles A. Coltman

JNCI Journal of the National Cancer Institute

Abstract

This predictive model allows an individualized assessment of prostate cancer risk and risk of high-grade disease for men who undergo a prostate biopsy.

References

	Year	Citations
The Influence of Finasteride on the Development of Prostate Cancer Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, New England Journal of Medicine	2003	2.5K
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter Ian M. Thompson, Donna K. Pauler, Phyllis J. Goodman, New England Journal of Medicine	2004	2.4K
Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower Ian M. Thompson JAMA	2005	688
Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination William J. Catalona JAMA	1997	664
Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial Fernand Labrie, Bernard Candas, Andr� Dupont, The Prostate	1999	332
Development of a decision-making tool to predict risk of prostate cancer: The cancer of the prostate risk index (CAPRI) test Scott A. Optenberg, Joseph Y. Clark, Michael K. Brawer, Urology Decision ScienceRisk AnalysisMedical Decision MakingOncologyRisk Management	1997	44

Page 1